Our current study exploited a novel therapeutic intervention targeting AXL [44], Notch1 [51], Myc [52], or SIRT1 [46] in an attempt to improve the management of androgen-refractory prostate cancers. This evidence concerns the gene AXL and prostate carcinoma.